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The deregulation of microRNA (miRNA) is frequently associated
with a variety of cancers, including hepatocellular carcinoma
(HCC). In this study, we identiﬁed 10 upregulated miRNAs
(miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522,
miR-518e, miR-525-3p, miR-512-3p and miR-518a-3p) and 10
downregulatedmiRNAs(miR-138,miR-214,miR-214#,miR-27a#,
miR-199a-5p, miR-433, miR-511, miR-592, miR-483-5p and miR-
483-3p) by Taqman miRNAs array and quantitative real-time
PCR (qRT–PCR) conﬁrmation. Additionally, we investigated the
expressionandpossibleroleofmiR-138inHCC.qRT–PCRresults
showed that miR-138 was downregulated in 77.8%(14/18) of HCC
tissues compared with adjacent non-tumor tissues. Overexpres-
sion of miR-138 reduced cell viability and colony formation by
induction of cell arrest in HCC cell lines and inhibited tumor cell
growth in xenograft nude mice. The use of miR-138 inhibitor in-
creased cell viability and colony formation in HCC cell lines and
tumor cell growth in xenograft nude mice. Using TargetScan pre-
dictions, CCND3 was deﬁned as a potential direct target of miR-
138. Furthermore, CCND3 protein expression was observed to be
negatively correlated with miR-138 expression in HCC tissues.
The dual-luciferase reporter gene assay results showed that
CCND3 was a direct target of miR-138. The use of miR-138 mimic
or inhibitor could decrease or increase CCND3 protein levels in
HCC cell lines. We conclude that the frequently downregulated
miR-138 can regulate CCND3 and function as a tumor suppressor
in HCC. Therefore, miR-138 may serve as a useful therapeutic
agent for miRNA-based HCC therapy.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers
worldwide (1). The development and progression of HCC is typical of
a multistage process, which is believed to involve the deregulation of
genes that are critical to cellular processes, such as cell cycle control,
cell growth, apoptosis and cell migration and spreading. In the past
decades, studies have focused on investigating the genes and proteins
underlying the development and progression of HCC (2). Recently, an
increasing number of reports have described a new class of small
regulatory RNA molecules termed microRNAs (miRNAs) that are
implicated in HCC progression (3).
MiRNAs are endogenous non-coding 20–22 nucleotide RNAs that
have been identiﬁed as post-transcriptional regulators of gene expres-
sion (4). The miRNAs mainly bind to the 3# untranslated regions
(UTRs) of target messenger RNAs (mRNAs), resulting in mRNA
degradation or the blockade of mRNA translation. Increasing evi-
dence showed that miRNAs have signiﬁcant roles in diverse biological
processes (5). Meanwhile, deregulation of miRNAs has been observed
in a wide range of human diseases, including cancer (6). In human
cancer, miRNAs can function as oncogenes or tumor suppressor genes
during tumor development and progression (7).
In this study, the expression proﬁles of 667 miRNAs were exam-
ined in human HCC and adjacent non-tumor tissues. A set of signif-
icantly differentially expressed miRNAs were identiﬁed in HCC
tissues. Further investigation revealed that miR-138, a frequently
downregulated miRNA in HCC, could induce cell cycle arrest in
HCC cell lines. Moreover, cyclin D3 (CCND3) was characterized
as a direct target of miR-138.
Materials and methods
Tissue specimens and cell lines
Eighteen pairs of human HCC and adjacent non-tumor tissues were obtained
from surgical specimens immediately after resection from patients undergoing
primary surgical treatment of HCC in the Eastern Hepatobiliary Surgery Hos-
pital, Shanghai, China. No patient had received preoperative irradiation or
chemotherapy. The samples were frozen in liquid nitrogen and stored at
 80C until use. Among these samples, three pairs were used for Taqman
low density miRNA array (TLDA) analysis and all of them were used for
quantitative real-time PCR (qRT–PCR) analysis. Clinical and pathological
information was extracted from the patients’ medical charts and pathology
reports (Table I). Written consent for tissue donation (for research purposes)
was obtained from the patients before tissue collection and the protocol was
approved by the Institutional Review Board of Eastern Hepatobiliary Surgery
Hospital and Second Military Medical University.
Human embryonic kidney cells (HEK293T) and human HCC cell lines
HepG2 and Huh7 were cultured in Dulbecco’s modiﬁed Eagle’s medium plus
10% fetal bovine serum (Invitrogen, Carlsbad, CA) at 37C in a humidiﬁed
atmosphere containing 5% CO2.
Taqman low density miRNA array
Total RNAwas isolated using mirVana miRNA isolation kit (Ambion, Austin,
TX). For miRNA complementary DNA (cDNA) synthesis, RNA was reverse
transcribed using the miRNA reverse transcription kit (Applied Biosystems,
Foster City, CA) in combination with the stem-loop Megaplex primer pool
(Applied Biosystems). Then, TLDAv2.0 was performed as the manufacturer’s
protocol. For each cDNA sample, 667 small RNAs were proﬁled. All PCR
reactions were performed on the 7900HT real-time PCR system (Applied
Biosystems). Cycling conditions were as follows: 95C for 10 min followed
by 40 cycles of 95C for 15 s and 60C for 1 min. Human U6 small RNAwas
used as an internal control to normalize RNA input. The data were analyzed by
SDS v2.3 software. In details, the Ct value is deﬁned as the fractional cycle
number at which the ﬂuorescence passes the ﬁxed threshold. The fold change
was calculated using the 2 DDCt method and presented as the fold-expression
change in tumors relative to their corresponding normal tissues after normal-
ization to the endogenous control.
Quantitative real-time PCR
Synthesis of cDNA and qRT–PCR analysis of miRNA expression was carried
out with TaqMan microRNA assay kits (Applied Biosystems) according to the
manufacturer’s protocol. Brieﬂy, total RNA was extracted using TRIzol Re-
agent (Invitrogen) from clinical samples or HCC cell lines and were used to
synthesize cDNAs with gene-speciﬁc primers. Reverse transcriptase (RT) re-
actions contained 100 ng RNA, 50 nmol/lstem-loop RT primers, 1  RT buffer,
0.25 mmol/l each of the deoxyribonucleotide triphosphates, 3.33 U/ll Multi-
Scribe reverse transcriptase and 0.25 U/ll ribonuclease inhibitor. The 15 ll
reactionswere incubatedfor30minat 16C,30 minat 42C,5 minat 85C and
then held at 4C. The cDNA product was used for the following qRT–PCR
analysis directly. The 20 ll PCR reaction included 1.33 ll RT product,
Abbreviations: CDK, cyclin-dependent kinase; cDNA, complementary DNA;
FDR, false discovery rate; GO, Gene ontology; HCC, hepatocellular carcinoma;
KEGG, Kyoto encyclopedia of genes and genomes; miRNA, microRNA;
mRNA, messenger RNA; NC, nonrelative control; qRT–PCR, quantitative
real-time–PCR; RT, reverse transcriptase; siRNA, small interfering RNA;
TLDA, Taqman low density miRNA array; UTR, untranslated region.
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1 min. PCR reactions were run on a StepOne Plus real-time PCR machine
(Applied Biosystems) and the data were analyzed by SDS v2.3 software same
as in TLDA.
The construction of luciferase reporter plasmids
The fragment of 3#UTR of CCND3 (1054–2061 nt, Genbank accession no.
NM_001136017.2) containing the two putative miR-138-binding sequences
(1279–1285 nt and 1346–1352 nt) was ampliﬁed with the primers 5#-
CCCTGGAGAGGCCCTCTGGA-3# (forward) and 5#-TTCCAAGAAGCCA-
AAGCCAG-3# (reverse). The PCR product was cloned into Fireﬂy luciferase
reporter vector pGL3 (Promega Corporation, Madison, WI), termed as pGL3-
CCND3-3#UTR. The plasmid which carried the mutated sequence in the two
complementary sites for the seed region of miR-138 (Figure 2A) was generated
based on pGL3-CCND3-3#UTR plasmid by MutanBEST Kit (Takara Bio, Shi-
ga, JP), termed as pGL3-CCND3-3#UTR-mut. Brieﬂy, a forward miR-138
mutagenic primer F1-GAT ACATAGTGGTCGATTCCTTTTGAACGCCCCC-
CCCCACCCC and a reverse miR-138 mutagenic primer R1-CAATTCTGTCC-
CATCAGCCTGGCCCSCCCCCSGCTSGSGTTG or a forward miR-138
mutagenic primer F2-CTGCATCTGTGGTCGAGCGCCTTTCCCAACT
CTAGCTGGGG and a reverse miR-138 mutagenic primer R2-GGAGGAG-
GAGCTTGACTAGCCACCGAAATGCAGACATGG, were synthesized and uti-
lized in PCR experiment as described by the manufacturer. Two point mutations
along the miR-138 seed binding sites were conﬁrmed by sequencing analyses.
Transfection
The transfections were carried out using FuGene HD transfection reagent
(Roche, Indianapolis, IN) following the manufacturer’s protocol. In brief,
2   104 HepG2 and Huh7 cells or 5   104 HEK293T cells in 24-well plate
were transfected with indicated plasmid DNA, miRNA duplex (GenePharma,
Shanghai,China),smallinterferingRNA(siRNA) (GenePharma)andcollected
24–48 h after transfection for assay.
Cell viability assay
Twenty-four hours after transfection, 1000 transfected HepG2 and Huh7 cells
were placed in a fresh 96-well plate in triplicate and maintained in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum for 5 days. Cells
were tested for proliferation per 24 h using Cell Titer-Blue cell viability assay
(Promega Corporation) according to the manufacturer’s instructions and the
ﬂuorescence value was recorded by multi-plate reader (Synergy 2; BioTek,
Winooski, VT).
Cell cycle analysis
Forty-eight hours after transfection, 1   105 transfected HepG2 and Huh7cells
were harvested, washed once in phosphate-buffered saline and ﬁxed in 70%
ethanol at 4C overnight. Staining for DNA content was performed with
50 mg/ml propidium iodide and 1 mg/ml ribonuclease A at room temperature
for 30 min. Populations in G0–G1, S and G2–M phase were measured by Cell
Lab Quanta SC ﬂow cytometry (Beckman Coulter, Fullerton, CA) and the data
were analyzed by FlowJo v7.6 Software.
Colony formation assay
Twenty-four hours after transfection, 2000 transfected HepG2 and Huh7cells
were placed in a fresh six-well plate in triplicate and maintained in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum for 2 weeks. Cell
colonies were ﬁxed with 20% methanol and stained with 0.1% coomassie
brilliant blue R250 at room temperature for 15 min. The colonies were counted
by ELIspot Bioreader 5000 (BIO-SYS, Karben, GE).
Tumorigenicity assays in nude mice.
Male BALB/c nude mice (5–6 weeks of age) were obtained from Shanghai
Experimental Animal Center (Shanghai, China). Animal handling and exper-
imental procedures were approved by the Animal Experiments Ethics Com-
mitteeof SecondMilitaryMedical University. Forinvivo tumorigenicity assay,
all pyrimidine nucleotides in the miR-138 mimic, miR-138 inhibitor or non-
relative control (NC) duplex were substituted by their 2#-O-methyl analogues
to improve RNA stability. MiR-138 mimic-or miR-138 inhibitor-transfected
HepG2 cells (1   105) were suspended in 100 ll phosphate-buffered saline
a n dt h e ni n j e c t e ds u b c u t a n e o u s l yi n t ol e f ts i d eo ft h ep o s t e r i o rﬂ a n ko fs i x
BALB/c nude mice, respectively. NC transfected or non-transfected HepG2
cells (1   105) were injected subcutaneously into right side of same 12 mice.
Tumor growth was examined daily and the tumor volumes were calculated
every week using the formula for hemi-ellipsoids: V 5length (cm)   width
(cm)   height (cm)   0.5236. After 5 weeks, the micewere sacriﬁced and the
tumors were dissected and photographed.
Dual-luciferase reporter assay
HEK293T cells seeded in 24-well plate in triplicate were cotransfected with
pGL3-CCND3-3#UTR or pGL3-CCND3-3#UTR-mut and miRNA-138 mimic
or non-relative control RNA duplex (NC duplex; GenePharma) by using Fu-
Gene HD transfection reagent. The pRL-TK (Promega Corporation) was also
transfected as a normalization control. Cells were collected 48 h after trans-
fection, and luciferase activity was measured using a dual-luciferase reporter
assay kit (Promega Corporation) and recorded by multi-plate reader (Synergy 2;
BioTek).
Western blotting
ProteinextractsfromHCCtissusesorHepG2cellswerepreparedbyamodiﬁed
RIPA buffer with 0.5% sodium dodecyl sulfate in the presence of proteinase
inhibitor cocktail (Complete mini; Roche). Twenty-ﬁve micrograms of protein
of HCC tissues and their adjacent non-tumorous tissues were electrophoresed
in 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis mini gels
and transferred onto polyvinylidene diﬂuoride membranes (Immobilon P SQ;
Millipore, Billerica, MA). After blocking with 5% non-fat milk, the mem-
branes were incubated with rabbit anti-cyclin D3 antibody (1:1000 dilution;
Epitomics, Burlingame, CA) or mouse anti-glyceraldehyde-3-phosphate de-
hydrogenase antibody (1:5000 dilution; Epitomics) at 4C overnight, followed
by incubation with horseradish peroxidase-conjugated goat anti-rabbit or goat
anti-mouse antibody (1:10000 dilution; KPL, Gaithersburg, MA) for 1 h at
room temperature. Finally, signals were developed with Super Signal West
Pico chemoluminescent substrate (Pierce, Rockford, IL), visualized by the
GeneGnome HR Image Capture System (Syngene, Frederick, MD) and ana-
lyzed by Gene tools (Syngene).
Prediction of miRNAs targets
To investigate the target genes of miRNAs and the conserved sites bound by
the seed region of miR-138, the TargetScan (http://www.targetscan.org/),
MiRanda (http://www.microrna.org/microrna/home.do) and PicTar (http://
pictar.mdc-berlin.de/) programs were used.
Gene ontology and Kyoto encyclopedia of genes and genomes pathway
analysis
The top 25% miRNA targets that had been assigned the highest numbers of
miRNA interaction sites were collected and subjected to Gene ontology (GO)
and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis. GO
analysis was applied to analyze the main function of the differential expression
genes according to the GO, which is the key functional classiﬁcation of Na-
tional Center for Biotechnology Information (8).Generally, Fisher’s exact test
and v2 test were used to classify the GO category, and the false discovery rate
(FDR) (9) was calculated to correct the P-value, the smaller the FDR, the
smaller the error in judging the P-value. The FDR was deﬁned as
FDR51   Nk
T , where Nk refers to the number of Fisher’s test P-values less than
v2 test P-values. P-values were computed for the GOs of all the differential
genes. Enrichment provides a measure of the signiﬁcance of the function: as
the enrichment increases, the corresponding function is more speciﬁc, which
helps us to ﬁnd those GOs with more concrete function description in the
experiment. Within the signiﬁcant category, the enrichment Re was given by
Re5

nf

n

Nf

N

,where nf is the number of differential genes within the
particular category, n is the total number of genes within the same category, Nf is
the number of differential genes in the entire microarray and N is the total
number of genes in the microarray (10). Similarly, pathway analysis was used
Table I. The data of patients (n 5 18)
Variable Value
Age (years) 48.5 ± 10.1
Gender (male) 14 (77.8%)
Tumor size
a (cm) 8.73
Tumor grade
Well-differentiated (G1–2) 7
Moderately-differentiated (G3) 11
Poorly-differentiated (G4) 0
TNM stage
I4
II 7
III 6
IV 1
TNM, tumor-node-metastasis.
aDiameter of the biggest nodule.
W.Wang et al.
1114to ﬁnd out the signiﬁcant pathway of the differential genes according to KEGG,
BiocartaandReatome.Still,theFisher’sexacttest andv2 testwereusedtoselect
the signiﬁcant pathway, and the threshold of signiﬁcancewas deﬁned by P-value
and FDR. The enrichment Re was calculated like the equation above (11–13).
Statistical analysis
Data are presented as mean ± SD. Comparisons were made by using a two-
tailed t-test or one-way analysis of variance for experiments with more than
two subgroups. Correlation analysis was made by using Spearman correlation
coefﬁcient. P ,0.01 was considered statistically signiﬁcant.
Results
Patient characteristics
HCC and adjacent non-tumor tissues were obtained from 14 male and
4 female patients and their proﬁles are shown in Table I. The average
age of these patients was 48.5 years (ranged from 35 to 71 years).
Eleven patients (61.1%) had tumors .5 cm, two (11.1%) had tumors
,2 cm and ﬁve (27.8%) had 2–5 cm tumors. Seven (38.9%) cases
werewell differentiated (I þ II) and 11(61.1%) cases were moderately
differentiated (III). Four patients (22.2%) were diagnosed at invasion
T1, seven (38.9%) at invasion T2, six (33.3%) at invasion T3 and one
(5.6%) at invasion T4.
Differential expression of miRNAs in HCC
The TLDA were performed in three pairs of HCC and adjacent non-
tumor tissues. Only miRNAs altered by at least 3-fold in all three pairs
of the samples were considered signiﬁcant candidates. Under these
strict criteria, 11 upregulated miRNAs and 12 downregulated miR-
NAs were identiﬁed. To validate the miRNA array data, qRT–PCR
was performed in 18 pairs of HCC tissues. Ten upregulated and 10
downregulated miRNAs showed consistent changes in .50% tumor-
ous tissues (Table II), of which miR-217, miR-520g, miR-522 and
miR-525-3p were upregulated in .70% tumorous tissues and
miR-199a-5p, miR-138, miR-483-5p and miR-511 were downregu-
lated in .70% tumorous tissues (Table II).
GO and KEGG pathways analysis of these deregulated miRNAs
The targets of the above 20 deregulated miRNAs were predicted by
TargetScan and the representative target genes were listed in Table II.
To judge the most signiﬁcant candidates and investigate the cellular
function, the signaling pathway and GOs of these target genes were
analyzed. The results showed that a wide variety of cellular processes
were featured signiﬁcantly in signaling pathways (Supplementary
Table S1 is available at Carcinogenesis Online). Many of these sig-
naling pathways, such as insulin, mitogen-activated protein kinase,
transforming growth factor-beta and Wnt signaling pathway, have
been shown to participate in the tumorigenesis (14–17). However,
some other signaling pathways have never been reported to play a role
in tumorigenesis, e.g. axon guidance. Among all these differentially
regulated signaling pathways, ‘regulation of actin cytoskeleton’ and
‘pathway in cancer’ appeared to be the most enriched two in both
upregulated and downregulated miRNA groups. A similar phenome-
non was observed in GOs analysis. Many cellular functions were
featured signiﬁcantly, of which the ‘signal transduction’ appeared to
be the most enriched one (Supplementary Table S2 is available at
Carcinogenesis Online). Based on these results, the miRNAs which
were involved in both signal transduction and the regulation of actin
cytoskeleton or pathway in cancer might be the most signiﬁcant can-
didates. MiR-520g, miR-483-5p, miR-138, miR-199a-5p, miR-217
and miR-518e were selected under the criteria for further studies.
Here, the studies on miRNA-138 were presented.
MiR-138 induces cell cycle arrest
The signiﬁcant reduction of miR-138 expression in HCC tissues in-
dicated possible biological signiﬁcance in tumorgenesis. At ﬁrst, the
effect of miR-138 on cell growth was evaluated in HepG2 and Huh7
Table II. The deregulated miRNA in Hepatitis B virus-associated HCC
miRNA Fold change P-value Validation
a Representative predicted targets
Upregulated miRNAs
hsa-miR-520g 9475.09 0.0023 13 (72.2%) VAPA, BET1, MMP2, GNAI3, PLCB1, PTPRJ, ENPP1, BMP6, ENAH, ARHGEF11
hsa-miR-519a 8204.48 0.0034 10 (55.6%) TGFBR2, MYLK, PAFAH1B1,ROCK2, PRDM4,VAPA, EDNRB, ERBB3, JAK1, RPS6KA3
hsa-miR-522 6178.34 0.0005 13 (72.2%) SORBS1, UBE2G1, RAB7A, PDCD6IP, WHSC1, KITLG, YWHAZ, UBE2Q2, CCND2,
UBE2K
hsa-miR-518e 4096.74 0.0016 11 (61.1%) RAP1B, NPAS2, SPRY4, MAP4K4, OGDH, WHSC1, EHMT1, RPS6KA1, JAK1, TRIP10
hsa-miR-525-3p 1489.49 0.0004 14 (77.8%) HES1, MAP4K4, CCND3, ITGA2B, FGFR1, EPHB4, NRAS, BAIAP2, CBL, WHSC1
hsa-miR-217 1080.33 0.0018 11 (59.4%) RPS6KA3, RAP1B, STK4, MAP4K4, WHSC1, CACNB1, SOCS5, NPAS2, OGDH, CUL5
hsa-miR-518b 982.85 0.0034 14 (77.8%) ATP11C, ATP8A1, ICK, AAK1, SOS1, ANLN, COX18, BCL11A, ATP1B1, LMO7
hsa-miR-512-3p 197.21 0.0045 10 (55.6%) SOCS3, WASL, AK1, RAP1A, PPAP2B, SSX2IP, ASH1L, MAPK1, VANGL2, EDNRA
hsa-miR-517c 130.92 0.0006 11 (61.1%) SMAD2, ABL2, UBE2D1, GPAM, RAB11FIP4, SH3GLB1, PPARGC1A, CCND3, PPP3CA,
CTBP1
hsa-miR-518a-3p 46.84 0.0023 10 (55.6%) RPS6KA3, RAP1B, STK4, MAP4K4, WHSC1, RAB22A, CACNB1, SOS2, OGDH, TFDP1
Downregulated miRNAs
hsa-miR-199a-5p 0.00237 0.0005 13 (72.2%) JAG1, NLK, CACNB2, GCNT2, ROCK1, VEGFA, PI4KA, ACACA, SERPINE1, PPP1R12A
hsa-miR-433 0.00310 0.0027 10 (55.6%) SORBS1, KRAS, EPAS1, CLTC, YWHAZ, PP3R1, CUL5, SMC1A, MYH9, GRB2
hsa-miR-592 0.01137 0.0035 11 (59.4%) PLXNA2, FOXO1, SMAD4, STX16, FOXO3, SLC8A1, ACACA, CSNK1A1, ACVR2A,
UBE2D3
hsa-miR-214# 0.01327 0.0061 11 (59.4%) PDGFRA, DLST, SEMA4C, JAG1, SMAD4, CASP9, CRY2, VTI1A, ACACA, WASL
hsa-miR-27a# 0.02207 0.0053 10 (55.6%) ELK1, IGF1, SSX2IP, CACNA2D2, AP2M1, MYH14, BAIAP2, ARFGAP2, PI4KA, SMAD5
hsa-miR-483-5p 0.03310 0.0034 14 (77.8%) MAP4K4, ARFGAP2, DAB2, ARHGEF12, SERPINE1, VPS4A, DTX2, STK3, ADRBK1,
ARRB2
hsa-miR-483-3p 0.03323 0.0051 12 (66.7%) ITPR2, PDGFB, PRKAR1A, KITLG, SMAD4, IGF1, ARRB2, VPS4A, MYH9, TGFBR2
hsa-miR-138 0.03727 0.0019 14 (77.8%) RMND5A, GPR124, CREB3L2, SLC35F1, SYT13, KLF11, AMMECR1, GTPBP1, SH2B3,
NFIX
hsa-miR-214 0.04213 0.0053 11 (59.4%) NOTCH2, ACOX1, RASSF5, RUNX1, CACNB1, CDK6, IRS2, ARHGEF12, VANGL2,
VASP
hsa-miR-511 0.07957 0.0049 13 (72.2%) SPRY1, MYH10, VTI1A, UBE2D1, SRF, NTRK2, SH3GLB1, IRS2, SMAD4, GPAM
GTP, guanosine triphosphate, IGF, insulin-like growth factor; MAPK, mitogen-activated protein kinase, MMP, matrix metalloproteinase; PDGF, platelet-derived
growth factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
aqRT–PCR was performed in 18 pairs of tumor and non-tumor tissues in HCC.
MiR-138 as a tumor suppressor in HCC
1115cells transfected with or not, miR-138 mimic, miR-138 inhibitor or NC
duplex. The expression of miR-138 was increased 25-folds (HepG2)
and 22-folds (Huh7) in cells transfected with 20 nM miR-138 mimic
but deceased 30-fold (HepG2) and 43-folds (Huh7) in cells transfected
with 20 nM miR-138 inhibitor (Figure 1A). From second day (HepG2)
or third day (Huh7) after the transfection, the viability of cells trans-
fected with miR-138 mimic signiﬁcantly decreased compared with that
of NC duplex transfected or non-transfected cells, but the viability of
cells transfected with miR-138 inhibitor signiﬁcantly increased
(Figure 1B). These results indicate miR-138 could inhibit cell growth.
To validate the inhibitory effect of miR-138 on cell growth, the
colony formation assay was performed in HepG2 and Huh7 transfected
with or not, miR-138 mimic, miR-138 inhibitor or NC duplex. As
showed in Figure 1C, HepG2 and Huh7 cells transfected with 20 nM
miR-138 mimic displayed much fewer and smaller colonies (218 or
161 colonies) compared with NC duplex transfected (783 or 729 col-
onies) and non-transfected cells (756 or 692 colonies), but cells trans-
fected with 20 nM miR-138 inhibitor displayed much more and larger
colonies (1238 or 1349 colonies).
To further conﬁrm the above ﬁndings, an in vivo mouse model was
used. For the duration of the treatment with miR-138 mimic or miR-
138 inhibitor for 5 weeks, tumor volume curves revealed a signiﬁcant
decrease in growth rates at the third, fourth and ﬁfth week after
treatment with miR-138 mimic and a signiﬁcant increase in growth
rates at the fourth and ﬁfth week after treatment with miR-138
inhibitor whereas no signiﬁcant differences intumorgrowth rates were
observed between the NC group and the control group (Figure 1D).
These results indicate that introduction of miR-138 signiﬁcantly inhib-
its tumorigenicity of HepG2 cells in xenograft nude mouse model.
To investigate the mechanism of inhibitory effect of miR-138, ﬂow
cytometry assay showed that the percentages of miR-138 mimic trans-
fected HepG2 and Huh7 cells in the G0–G1 phase were 18% (HepG2)
and 11% (Huh7) higher than that of NC duplex transfected or non-
transfected cells, which paralleled with a 44% (HepG2) and 38%
(Huh7) decrease in the S phase (Figure 1E). In miR-138 inhibitor-
transfected cells, the percentages of cells in the G0–G1 phasewere 8%
(HepG2) and 6% (Huh7) less than that of NC duplex transfected or
non-transfected cells, which paralleled with a 14% (HepG2) and 19%
(Huh7) increase in the S phase (Figure 1E). These results indicate
miR-138 could inhibit HepG2 and Huh7 proliferation by inducing cell
cycle arrest at G1/S phase.
CCND3 is a direct target of miR-138
It is generally accepted that miRNAs exert their function through reg-
ulating the expression of their downstream target genes. CCND3 was
predicted as a potential target of miR-138 by TargetScan and miRanda
but not by PicTar. The 3#UTR of CCND3 mRNA contained a comple-
mentary site for the seed region of miR-138 (Figure 2A). CCND3 was
found to be upregulated in 72.2% (13 of 18) HCC tissues compared
Fig. 1. The effect of miR-138 on cell viability (B), colony formation(C), xenograft tumor growth (D) and cell cycle (E). (A) The expression of miR-138 in HepG2
and Huh7 cells with or without transfection of miR-138 mimic, miR-138 inhibitor or NC duplex. (B) The effect of miR-138 on cell viability of HCC cell lines.
(C) The effect of miR-138 on colony formation of HCC cell lines. (D) The effect of miR-138 on the tumor growth in xenograft nude mice. (E) The effect of
miR-138 on cell cycle of HCC cell lines. Representative results (B, C and E) in HepG2 and Huh7 cells transfected with miR-138 mimic, miR-138 inhibitor,
NC duplex or not. Column, mean of three independent experiments; bars, SD;  P , 0.01 and   P , 0.001. Representative results (D) in HepG2 transfected with
miR-138 mimic, miR-138 inhibitor, NC duplex or not.  P , 0.01.
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1116with adjacent non-tumor liver tissues (Figure 2B). Furthermore, a neg-
ative correlation was found between the upregulated CCND3 protein
and downregulated miRNA-138 (r 5  0.730, P , 0.01) (Figure 2C).
These results indicated that miR-138 may be associated with CCND3
and both of them may be involved in HCC tumorigenesis.
To validate whether CCND3 is a direct target of miR-138, a human
CCND3 3#UTR fragment containing wild-type or mutant miR-138
binding sequence (Figure 2A) was cloned downstream of the ﬁreﬂy
luciferase reporter gene in pGL3. In HEK293 cells cotransfected with
the reporter plasmids and miR-138 mimic or NC duplex, the lucifer-
ase activity of the reporter that contained wild-type 3#UTR was sig-
niﬁcantly suppressed by miR-138 mimic, but the luciferase activity of
mutant reporter was unaffected (Figure 2D), indicating that miR-138
may suppress gene expression through miR-138 binding sequence at
the 3#UTR of CCND3. Furthermore, transfection of miR-138 mimic
decreased CCND3 expression and transfection of miR-138 inhibitor
increased CCND3 expression in HepG2 cells at protein (Figure 2E)
but not mRNA level (data not shown), suggesting that CCND3 ex-
pression could be inhibited by miR-138 at post-transcriptional level.
Together, the results show that miR-138 could regulate the expression
of endogenous human CCND3 by directly targeting the 3#UTR of
CCND3 mRNA and human CCND3 is a new target of miR-138.
CCND3 knockdown could induce cell cycle arrest
To identify whether inhibition of CCND3, just like miR-138 restora-
tion, also resulted in HCC repression, the effects of knockdown of
CCND3 on cell growth were examined. First, HepG2 cells were trans-
fected with or not, CCND3 siRNA or control siRNA. Seventy-two
hours after transfection, a dose-dependent knockdown of CCND3 was
observed in HepG2 cells (Figure 3A). In cell viability assay and cell
cycle analysis, in vitro knockdown of CCND3 repressed cell viability
(Figure 3B), induced cell cycle arrest (Figure 3C) and inhibited the
colony formation (Figure 3D). The similar data were obtained in
Huh7 cells transfected with CCND3 siRNA (data not shown). These
Fig. 2. CCND3 is a direct target of miR-138. (A) The putative miR-138 binding sequence in the 3#UTR of CCND3 mRNA. Mutation was generated on the
CCND3 3#UTR sequence in the complementary site for the seed region of miR-138. (B) The expression of CCND3 in 18 paired HCCs tumor tissues (T) and
adjacent non-tumor tissues (N). (C) The negative correlation between the expression of miR-138 and CCND3 in paired HCC tissues. The relative quantity of miR-
138 in HCC tumor tissues compared with adjacent non-tumor tissues (T/N) was showed after normalized to U6. The relative quantity of CCND3 protein in HCC
tumor tissues compared with adjacent non-tumor tissues (T/N) was showed after normalized to glyceraldehyde-3-phosphate dehydrogenase. (D) Suppressed
luciferase activity of wild-type 3#UTR of CCND3 by miR-138 mimic. HEK293T cells were cotransfected pGL3-CCND3-3#UTR or pGL3-CCND3-3#UTR-mut
and miR-138 mimic or NC duplex. Fireﬂy luciferase activity of each sample was measured 48 h after transfection and normalized to Renilla luciferase activity.
(E) The expression of endogenous CCND3 regulated by miR-138. The expression level of endogenous CCND3 in HepG2 cells was analyzed 48 h after
transfection with miR-138 mimic, miR-138 inhibitor or NC duplex by western blotting. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal
control. Column, mean of three independent experiments; bars, SD;  P , 0.01.
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cell cycle arrest by miR-138.
Discussion
MiRNAs were found to be frequently deregulated in HCC, and some
speciﬁc miRNAs were found to be associated with the clinicopatho-
logical features of HCC, such as metastasis, recurrence and prognosis
(18–20). Moreover, compelling evidence demonstrates that miRNAs
haveimportant rolesinHCC progressionand directlycontributeto the
cell proliferation, avoidance of apoptosis and metastasis of HCC.
Identifying the miRNAs and their targets that are essential for HCC
progression may provide promising therapeutic opportunities.
In this study, with TLDA and real-time reverse transcription–PCR
conﬁrmation, 10 upregulated miRNAs (miR-217, miR-518b, miR-
517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-
512-3p and miR-518a-3p) and 10 downregulated miRNAs (miR-138,
miR-214, miR-214#, miR-27a#, miR-199a-5p, miR-433, miR-511,
miR-592, miR-483-5p and miR-483-3p) were identiﬁed in HCC. Im-
portant of these 20 deregulated miRNAs, only miR-199a-5p was re-
ported to contribute to the increase of cell invasion by functional
deregulation of DDR1 activity in HCC (21) and regulate Brm subunit
of SWI/SNF in human cancers (22), and the other 19 deregulated
miRNAs were ﬁrst reported to be involved in HCC tumorigenesis.
MiR-27a#, miR-214#, miR-518a-3p and miR-518e have never been
reported in literature. The rest 15 miRNAs were reported in various
cancer but not HCC. For example, the upregulated miR-512-3p and
miR-525-3p were associated with a cisplatin-resistant phenotype in
human germ cell tumors (23). The upregulated miR-519a and down-
regulated miR-511 and miR-485-5p were associated with histological
subtypes in ovarian cancers (24). MiR-517c and 520g promotes invitro
and invivo oncogenicity, modulates cell survival and robustly enhances
growth of untransformed human neural stem cells in neuroectodermal
brain tumors (25). MiR-433 could regulate tumor-associated proteins
GRB2 in gastric carcinoma (26). MiR-592 was reported to be associ-
ated with the stepwise progression for transformation from normal co-
lon to carcinoma (27). Thus, the role of these deregulated miRNAs in
HCC tumorigenesis is pretty worthy to be investigated.
Compared with the previous version, the more newly found miR-
NAs (337 updated miRNAs) were proﬁled in TLDAv2.0, which may
be the reason so many new differentially expressed miRNAs were
identiﬁed in this study. Meanwhile, very strict criteria of selection
deﬁned in TLDA (signiﬁcantly different in all three pairs of HCC
tissues) led to the absence of somewell-known HCC-related miRNAs.
Such as miR-21 (28), miR-122 (29,30), miR-16 (31) and miR-29
(32,33) were excluded for their signiﬁcantly differential expression
only in two pairs of HCC tissues, and miR-181 (34), miR-221 (35,36),
miR-125 (37) and miR-101 (38) were excluded for their differential
expression in only one pair of HCC tissues or no differential expres-
sion at all. Using such strict criteria, we might miss some important
candidates but catch some unique ones. Fortunately, qRT–PCR and
follow-up studies proved that our strategy helped ﬁnd the above new
deregulated miRNAs.
All of HCC patients included in this study were HBsAg positive.
Therefore, the expression patterns of identiﬁed miRNAs may mainly
represent the alterations in Hepatitis B virus-positive HCC, which
may partially account for the inconsistency between the others and
our results. Although the HCC tissues from four tumor grades (G1–
G4) were included, we were unable to perform statistical comparison
on the proﬁles of differentially expressed miRNAs among four tumor
grades due to the quantity restriction. Future studies including larger
size of four tumor grades samples are required to elucidate the miR-
NAs associated with the clinicopathological features of HCC, which
might severed as the biomarker for HCC.
KEGG pathway and GO enrichment analysis, which was based on
the reported and predicted target genes of these deregulated miRNAs,
were appliedtoidentify which particular functions andpathways were
enriched among genes controlling distinctive characters between HCC
and adjacent non-tumor tissues. As a result, KEGG pathway analysis
showed that proliferative (cell cycle, mitogen-activated protein kinase
Fig. 3. CCND3couldinducecellcyclearrest.(A)CCND3siRNAefﬁcientlyinhibitstheexpressionofCCND3.TheexpressionofendogenousCCND3wasanalyzed
48 h after transfection with CCND3 siRNA or NC siRNA by western blotting. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control.
(B) CCND3 knockdown reduced cell viability of HCC cell lines. Representative results of cell viability in HepG2 cells transfected with CCND3 siRNA and NC
siRNA or not. (C) CCND3 knockdown induced cell cycle of HCC cell lines. Representative results of cell cycle in HepG2 cells transfected with CCND3 siRNA NC
siRNA or not. (D) CCND3 knockdown inhibited colony formation of HCC cell lines. Representative results of colony formation in HepG2 cells transfected with
CCND3 siRNA and NC siRNA or not. Column, mean of three independent experiments; bars, SD;  P , 0.01.
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adhension), survival (transforming growth factor-beta and ErbB) and
oncogenic (renal cell carcinoma and pancreatic cancer) signaling path-
ways were abundant among the signiﬁcantly enriched ones. Further-
more, the GOs related to signal transduction (signal transduction, small
guanosine triphosphatase-mediated signal transduction, protein–amino
acid phosphorylation and nerve growth factor receptor signaling
pathway) and cell growth (cell differentiation, cell division, positive
regulation of cell proliferation, cell cycle and multicellular organism
development) represented up to 37% of the signiﬁcantly enriched
GOs. As expected, various cell process and signal pathways were
involved in HCC tumorigenesis. To narrow down the scope of study
and judge the most signiﬁcant candidates, the intersection of signal
transduction and regulation of actin cytoskeleton and pathway in
cancer was selected for follow-up study.
Based on TargetScan search, miR-138 has 388 conserved targets,
32% of which belong to the intersection of signal transduction and
regulation of actin cytoskeleton and pathway in cancer. In addition,
we showed that miR-138, frequently downregulated in human HCC
tissues, could suppress colony formation and induce cell cycle arrest
in hepatoma cell lines and inhibit tumor growth in xenograft nude
mice model. These results suggest the important role of miR-138 in
HCC tumorigenesis. Reduced expression of miR-138 has been ob-
served in different types of cancers (39–43) but not HCC. MiR-138
plays an important role in tongue squamous cell carcinoma cell mi-
gration and invasion by concurrently targeting RhoC and ROCK2
(39). MiR-138 could inhibit the expression of HIF-1a and regulate
the apoptosis and migration of clear cell renal cell carcinoma cells
(40). MiR-138 enhanced cell migration and invasion by targeting
enhancer of zeste homologue 2 (EZH2) in squamous cell carcinoma
cell lines (41). MiR-138 may play an important role in cancer initia-
tion and progression by regulation of FOSL1 in squamous cell carci-
noma (42) or G protein alpha-inhibiting activity polypeptide 2
(GNAI2) in tongue squamous cell carcinoma (43). We identiﬁed
CCND3 as a target of miR-138 in HCC, which may provide new
insights into the mechanisms underlying tumorigenesis. CCND3 is
expressed in nearly all proliferating cells and could promote the cell
cycle start (44). Liu et al. (45) reported miR-16 family (including
miR-16, miR-195 and miR-424) could induce cell cycle arrest by
targeting CCND3, CCNE1 and cyclin-dependent kinase (Cdk)-6. In
TLDA analysis, miR-16 and miR-195 showed no difference in all
three pairs of HCC tissues and miR-424 showed signiﬁcant difference
only in two of three pairs of HCC tissues, which suggest miR-16
family may not play important role in HCC tumorigenesis. Thus,
we didn’t verify the regulation of miR-16 family on CCND3. The
cell cycle is regulated by a family of the CDKs and their activating
partners (cyclins). The G1/S phase transition is regulated primarily by
D-type cyclins (D1, D2 or D3) in complex with CDK4/CDK6 and
E-type cyclins (E1 or E2) in complex with CDK2. These complexes
cooperate in phosphorylating and preventing Rb binding to E2F, thus
activating E2F-mediated transcription and drivingcells from G1 into S
phase (46). Whether the CDK/pRb/E2F pathway is involved in the
miR-138 induction of cell cycle arrest needs further study. On the
other hand, Wang et al. (47) showed that CCND3–cdk4/cdk6 specif-
ically phosphorylate C/EBP at Ser193 and support growth-inhibitory
C/EBP–cdk2 and C/EBP–Brm complexes in differentiated cells , but
we showed the promotion of growth of CCND3 regulated by miR-138
in HCC cell lines. This discrepancy may be due to different cell lines
and different subjects of study. CCND3 is expressed abroad, suggest-
ing that it has many different cell functions. CCND3 had been re-
ported to be involved in the promotion of cell growth by several
groups (48–52). Under the speciﬁc study design, the researchers could
investigate only one or some aspects of CCND3 but all of it, which is
needed to be further investigated.
In summary, we report the expression patterns of altered miRNAs
in HCC and the potential role of miR-138 in tumorigenesis. Our data
suggest the frequently downregulated miR-138 can regulate CCND3
and function as a tumor suppressor in HCC. Therefore, miR-138 may
serve as a useful therapeutic agent for miRNA-based HCC therapy.
Supplementary material
Supplementary Table S1 and S2 can be found at http://carcin.
oxfordjournals.org/.
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